US Bancorp DE Sells 30,125 Shares of Bristol-Myers Squibb Co (BMY)

US Bancorp DE trimmed its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,192,310 shares of the biopharmaceutical company’s stock after selling 30,125 shares during the quarter. US Bancorp DE’s holdings in Bristol-Myers Squibb were worth $136,099,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Principal Financial Group Inc. raised its stake in Bristol-Myers Squibb by 7.9% during the 1st quarter. Principal Financial Group Inc. now owns 3,094,134 shares of the biopharmaceutical company’s stock worth $195,704,000 after acquiring an additional 225,999 shares in the last quarter. DnB Asset Management AS increased its stake in Bristol-Myers Squibb by 0.3% in the second quarter. DnB Asset Management AS now owns 321,762 shares of the biopharmaceutical company’s stock valued at $17,806,000 after purchasing an additional 900 shares during the period. Rockland Trust Co. increased its stake in Bristol-Myers Squibb by 5.5% in the second quarter. Rockland Trust Co. now owns 68,152 shares of the biopharmaceutical company’s stock valued at $3,772,000 after purchasing an additional 3,547 shares during the period. IFM Investors Pty Ltd increased its stake in Bristol-Myers Squibb by 44.9% in the second quarter. IFM Investors Pty Ltd now owns 73,860 shares of the biopharmaceutical company’s stock valued at $4,087,000 after purchasing an additional 22,871 shares during the period. Finally, Fisher Asset Management LLC increased its stake in Bristol-Myers Squibb by 0.7% in the second quarter. Fisher Asset Management LLC now owns 581,310 shares of the biopharmaceutical company’s stock valued at $32,170,000 after purchasing an additional 4,229 shares during the period. 72.29% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have commented on BMY. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, July 14th. Credit Suisse Group lifted their price objective on shares of Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. BMO Capital Markets restated a “hold” rating on shares of Bristol-Myers Squibb in a research note on Sunday, July 22nd. Barclays lifted their price objective on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a research note on Friday, October 12th. Finally, William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Monday, October 22nd. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $62.42.

Shares of NYSE:BMY opened at $50.69 on Friday. The stock has a market capitalization of $82.49 billion, a PE ratio of 16.84, a PEG ratio of 1.41 and a beta of 1.08. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. Bristol-Myers Squibb Co has a fifty-two week low of $46.94 and a fifty-two week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.18. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. On average, equities analysts predict that Bristol-Myers Squibb Co will post 3.87 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, November 1st. Stockholders of record on Friday, October 5th were issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 3.16%. The ex-dividend date of this dividend was Thursday, October 4th. Bristol-Myers Squibb’s payout ratio is 53.16%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Story: What are the benefits of buying treasury bonds?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply